Hans Weverling is a Project Director Strategic Projects within the Large Molecule MAKE Asset Management team, based at the Leiden Janssen Biologics Site, the Netherlands.
Currently Hans is leading the Project to establish a new manufacturing and QC testing capability for Lentiviral Vector for Janssen in Leiden. Before this he was overall responsible for the Leiden COVID Manufacturing Readiness program since early 2020. Hans did join Janssen Biologics 10 years ago as Site Engineering Lead.
Hans graduated as M.Sc. in Chemical Engineering from the Delft University of Technology and has over 25 years of experience in Engineering, Qualification, Quality Assurance, Supply Chain and Project Management, obtained both in local (NL) and global roles in the pharmaceutical and excipients industry.